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Osteoarthritis-related changes in joint space measurements over time are small and sensitive to 
measurement error. The Reliable Change (RC) index determines whether the magnitude of 
change observed in an individual can be attributed to true change. This study aimed to examine 
the RC index as a novel approach to estimating osteoarthritis progression. 
Methods: 
Data from 167 men and 392 women with knee osteoarthritis (diagnosed using the ACR criteria) 
randomised to the placebo arm of the 3-year Strontium Ranelate Efficacy in Knee Osteoarthritis 
triAl (SEKOIA) and assessed annually. The RC index was used to determine whether the 
magnitude of change in joint space width (JSW) on radiographs between study years was likely 
to be true or due to measurement error.   
Results: 
Between consecutive years, 57 to 69% of participants had an apparent (change less than 0) 
decrease in JSW, while 31% to 43% of participants had annual changes indicating 
improvement in JSW.  The RC index identified decreases in JSW in only 6.0% between 
baseline and year 1 and 4.5% between the remaining study years. The apparent increases in 
JSW were almost eliminated between baseline and year 1, and between years 1 and 2 only 





The RC index provides a method to identify change in JSW, removing many apparent changes 
that are likely to be due to measurement error. This method appears to be useful for assessing 





















Significance and Innovations: 
- The aim of this research was to assess the effectiveness of the reliable change index as 
a novel approach to estimating OA progression, to date no studies have been 
identified that apply the RC index methodology within musculoskeletal research.  
 
- Interestingly, the reliable change index provides a useful method to identify change in 
joint space width, removing many of the apparent changes that are likely to be due to 
measurement error. When compared to crude differences in joint space width 
measurements, implementation of the reliable change index dramatically reduced the 
proportions of study participants that were identified as having statically reliable 
change. 
 
- This method appears to be useful for assessing change in JSW clinical and research 














Osteoarthritis (OA) is one of the most widespread musculoskeletal disorders worldwide (1, 2), 
and the knee is a commonly affected joint (3). During natural disease progression the joint 
affected will have dramatic structural changes, which lead to increasing levels of pain and 
disability for the sufferer.   
 
Although pain is the most commonly reported manifestation of knee OA (5), it is important to 
be able to quantify structural disease progression  to aid in understanding the risk factors for 
OA progression and to evaluate non-pharmacological and pharmacological treatments.  In 
epidemiological studies of knee OA, monitoring of structural disease progression has 
conventionally been based on a radiographic definition of knee OA (6), and knee joint space 
width (JSW), as a continuous measure, is currently the only Food and Drug Administration 
(FDA) approved endpoint for clinical trials assessing potential disease-modifying OA drugs 
(7).  JSW refers to measurement of the minimum medial tibiofemoral interbone distance and 
is assessed in a standard metric scale of millimetres. Knee JSW measurements are small, and 
in knees from healthy individuals, maximum values are around 8mm (8). However it has also 
been estimated that joint space measurements could be in error by up to 1mm (9), making it 
difficult to distinguish real deterioration in disease from measurement error. Previous studies 
have demonstrated that both the technique used to read the radiograph and positioning of the 





To date, no single gold standard statistical method is recommended in epidemiological studies 
that focus on disease progression through monitoring JSW measurements. When JSW 
measurements have been shown to be normally distributed, OA disease progression has been 
compared between groups using the simple method of calculating the mean difference between 
measurements, and then testing whether group differences are significant using such statistical 
techniques as paired t-tests (12). Non-parametric rank comparisons have also been used to 
compare structural change if JSW measurements have a skewed distribution (13). However, 
such statistical techniques will only reveal differences in means between groups or indicate 
whether a population mean joint space has changed over time; such methods give no 
information on changes within individuals. An individual’s change is the observed difference 
between two measurements taken at different times, and this may be dominated by 
measurement error in either or both measurements. In addition to obscuring disease 
deterioration, measurement error may lead to an apparent increase in joint space being 
observed. Due to the pathological process associated with OA i.e. cartilage volume loss, with 
ultimate involvement of underlying bone, it can be hypothesized that any significant observed 
increase in JSW arises as a result of measurement error. Therefore it is important, in both 
research and clinical settings, to minimise the effect of measurement error to identify 
differences that are more likely to be due to real change in disease. In research, it is important 
to ensure that the effects of any treatment or behavioural factors that are being related to disease 
progression are correctly identified. In a clinical setting, identification of rapid radiological 
progression may inform clinical management.  
  
The Reliable Change (RC) index is a statistical method for identifying whether an observed 
change within an individual is meaningful in the presence of measurement error (14). The RC 




be true or whether it is attributable to measurement error;  the greater the error in the 
measurement under investigation, the lower the likelihood that an observed change can be 
attributed to deterioration.  
 
To date, the RC index has been mainly used in health psychology, and little is known about its 
value outside this setting (15).  We therefore assessed the use of the RC index in a clinical 
research setting by implementing the index as a novel approach to estimate OA progression. 
We considered measurements of knee JSW taken at yearly intervals, within the control arm of 
an international, multicentre, randomised controlled trial of therapy for knee OA RC index 
results were compared with crude differences, and the well-recognised cut-points of 0.5 and 





This study uses data from patients randomised to the placebo arm of the 3-year Strontium 
Ranelate Efficacy in Knee OsteoarthrItis triAl (SEKOIA) (17). This was an international trial 
established to assess the effect of a drug treatment, strontium ranelate, on radiological and 
clinical progression of OA in the knee joint. Patients were recruited into the trial between 2006 
and 2008 from 98 study centres across 18 different countries and were randomised to either a 
drug regime of strontium ranelate 1g/day, strontium ranelate 2 g/day, or a placebo treatment. 
Participants were recruited from secondary care establishments where they were already 




Caucasian men and women aged over 50 years had to have a primary diagnosis of knee OA as 
defined by the clinical criteria of the American College of Rheumatology (ACR) (18). On 
radiograph, patients had to have knee K&L grade 2 or 3 (19); and JSW between 2.5mm and 
5mm at an inclusion screen and predominant OA of the medial tibiofemoral compartment. The 
SEKOIA study conformed to the principles of the Declaration of Helsinki and the trial is 
registered (ISRCTN41323372).  
 
Radiographs were performed at the time of selection and then annually on the target knee, using 
a standardised technique described elsewhere (20). The radiographer recorded a fixed flexion 
posterioanterior view (fixed angle 10°), using a SynaFlexerTM positioning frame (BioClinica 
(formerly Synarc), San Francisco, USA) (21). All radiographs were measured centrally 
(INSERM UMR 1033, Lyon, France) by a single reader blinded to treatment allocation and 
participant identity. Minimal JSW (mm) at the medial tibiofemoral compartment was measured 
using a standardised computer-assisted method (22). Radiological progressors were defined as 
those whose joint space changed by more than 0.5mm or 0.8mm over the 3 year duration of 
SEKOIA, as per the definition developed by Bruyere et al in 2005(16) (23) .   
 
Reliable change index 
The RC index was first developed in 1991 by Jacobson and Truax (14). The principle behind 
the index is to determine whether the magnitude of change observed in a study participant can 
be attributed to true change, i.e. the change observed is more than could be explained by the 
unreliability of the measure. Several variations of the RC index have been proposed (24), 




measurements differ from their previous measurements. All variations of the RC index follow 
the same fundamental expression: 




where 𝑌 is the study participant’s measurement at the latter time point, 𝑌′ represents the 
predicted measurement for the study participant at the latter time point of interest  and 𝑆𝐸 is 
the standard error of the score. The different approaches to the RC index vary in how they 
determine the different elements of the RC index. The version of the RC index that will be 
explored within this study was  developed by Christensen and Mendoza (25). The RC index 
formula for each study participant, which produces a standardised score (RC index) is: 






The predicted score is represented by the study participant’s measurement time point 1, 𝑋1, and 
the same study participant’s actual measurement at time point 2 is 𝑋2. The standard error is 
derived using 𝑆1
2and 𝑆2
2 which are the variances of the measurements at time point 1 and 2 
respectively, 𝑆1 and 𝑆2 are the standard deviations of the measurements at time point 1 and 2 
respectively and 𝑟𝑥𝑦 is the Pearson’s correlation coefficient between the measurements at the 
two time points. Using this version of the RC index does not require the assumption of equal 
variance in measurements between time points. 
 
The RC index calculation yields a standardised z-score (i.e. the scores have a mean of 0 and a 
standard deviation of 1). Following the convention of using 5% level of statistical significance 




indicating that the change observed reflects more than the fluctuations in the measurement 
procedure. Each study participant’s RC index score can be categorised into one of three 
categories: an increase (RC index > 1.96), a decrease (RC index<-1.96) or stable (RC index 
between -1.96 and 1.96). A magnitude of change threshold can be calculated from the standard 
error derived during the calculation of the RC index, with a level of change in JSW that can be 
considered statistically reliable being calculated as 1.96*√𝑆1
2 + 𝑆2
2 − 2𝑆1𝑆2𝑟𝑥𝑦  .  
 
Statistical analysis  
Study participants’ continuous characteristics were checked for normality and summarised 
using means and standard deviations (SD). Crude differences in JSW were calculated between 
each SEKOIA study visit to provide a change in JSW in millimetres per year between each 
study year. The RC index was calculated between each SEKOIA study visit as described above 
for all study participants. All analyses were undertaken using STATA 13 [StataCorp. 2013. 




In the SEKOIA study, 559 patients were randomised to the placebo arm; demographic 
characteristics of these participants are presented in Table 1. On entry, participants had a 
median disease duration of just over 4 years, with men having suffered from knee OA longer 
than women. The majority of participants (63%) had Kellgren and Lawrence grade 2 at 




62.8 (7.5) years, with the mean for men being greater than for women, at 63.8 (7.8) and 62.3 
(7.3) years respectively. The mean (SD) JSW at baseline was 3.51 (0.83) mm, which reduced 
to 3.15 (1.00) mm by the end of the study. The minimum JSW at baseline was 0.65mm, 
reducing to 0.38mm during the duration of the study and the largest individual reduction in 
JSW over the study was 3.34mm.  
  
The 472 intention-to-treat placebo population were used here to assess change in JSW; table 2 
and table 3 present the crude changes and RC index results across all SEKOIA study years.  
 
Of the 465 study participants who had knee JSW measurement at baseline and year 1, nearly 
70% had either no change or an apparent decrease in joint space width over the year when 
assessing using crude change, and this figure was nearly 60% between the remaining study 
years (Table 2). An RC index value was calculated for the differences in measurements 
between each SEKOIA study visit for each study participant. The SD at baseline for all JSW 
measurements was 0.82 and therefore the variance of JSW measurements at baseline was 0.67, 
while for all JSW measurements at year 1 the SD was 0.92 and the variance 0.84. The 
correlation between the two time points was 0.84. As an example, a participant with a baseline 
JSW of 4.841mm, and a JSW at year 1 of 3.981mm, the RC index value would be: 
3.981 − 4.841
√0.67 + 0.84 − 2 ∗ 0.82 ∗ 0.92 ∗ 0.84
=  −1.75 
Thus the RC index for the study participant indicates that no statistically significant change in 
JSW has occurred. Performing this calculation for each study participant between baseline and 
year 1 indicated that 28 (6.0%) study participants had an RC index less than -1.96 when 




statistically reliable decrease in JSW was observed that was larger than would be expected 
through fluctuation in the joint space measurements or measurement error. A similar pattern 
was observed between year 1 and year 2, and between year 2 and year 3, with 4.5% and 4.0% 
respectively having a statistically significant reliable decrease in knee joint space 
measurements between these years.  
 
Conversely, around 30% of study participants were identified as having an increase in crude 
JSW measurement between baseline and year 1, and approximately 42% of study participants 
were identified as having a crude increase between year 1 and year 2, or between year 2 and 
year 3. Using the RC index calculation, 5 study participants (1.1%) had an RC index greater 
than 1.96 when the observed differences between baseline and year 1 were assessed. These 5 
study participants are of note as they appear to have had an increase in JSW greater than can 
be explained by the fluctuations of an imprecise measurement procedure. Use of the RC index 
for measurements between year 1 and year 2, and between year 2 and year 3 indicated that only 
5 (1.3%) and 3 (0.9%) study participants respectively had an increase in JSW during those time 
periods. No study participants were found to be consistently identified as having a statistically 
significant reliable increase or decrease across all the following time periods: between baseline 
and year 1, between year 1 and year 2, and between year 2 and year 3.  
 
Of the 336 study participants with measurements at baseline and year 3, 78% had crude 
decreases in JSW over the 3-year duration, with nearly 36% having had a decrease in JSW 
more than 0.5mm and 18.5% having had JSN of 0.8mm or more. This measure of progression 
also identified a greater number of study participants with a decrease in knee JSW than the 




who were identified as having a crude increase in JSW between baseline and year 3 (74 study 
participants) only 1 (0.3%) study participant was still identified as having an increase when 
using the RC index score.  
 
All RC index values were normally distributed, and a magnitude of change in millimetres 
(threshold) was calculated by transforming the RC index results to give a change in JSW above 
which it can be said that statistically reliable change occurred. When calculating the magnitude 
of change in millimetres using the RC index the magnitude varied between 0.85mm to 1.23mm 
for the different study periods under consideration.  
 
Very similar patterns were seen when RC index scores were calculated for men and women, 
and by K&L grade separately.  
 
Discussion 
The aim of this study was to assess the effectiveness of the RC index as a novel approach to 
estimating OA progression, through assessment of knee JSW at yearly intervals. Although it is 
highly unlikely individual disease progression would be classified using the crude difference 
alone, if the measurements of the crude differences were taken in isolation it would lead to the 
conclusion that, between baseline and year 1, 70% of those study participants under observation 
had a worsening of their knee OA. However use of the RC index indicates that only 6.0% (28) 
of study participants had a statistically reliable decrease in observed JSW that was larger than 
would be expected through measurement error in joint space measurements between baseline 




simple differences can reliably be considered to have had a decrease in joint space. Similar 
patterns were observed between years 1 and 2, and between years 2 and 3. Considerably more 
study participants, 10.7% (36), had a statistically reliable decrease in observed change in JSW 
across the total duration of the SEKOIA trial indicating that reliable change becomes easier to 
detect when longer time periods exist between joint space measurements. This in part may be 
explained by there having been greater time for disease progression to have occurred, allowing 
for potentially greater deterioration, which can be more easily distinguished from the 
measurement error that is still present.  
 
Conversely, around 31% of study participants from between baseline and year 1, and 
approximately 42% of study participants between year 1 and year 2, or between year 2 and year 
3 were identified as having an absolute increase in JSW. As real increases are extremely 
unlikely, this shows the impact of measurement error; if crude differences are assessed, without 
taking any account of measurement error, over a third of study participants would appear to 
have had some improvement in their knee OA condition. Use of the RC index identified a 
markedly lower number of 5 participants (1.1%) between baseline and year 1, 5 (1.3 %) 
between years 1 and 2, and only 3 (0.9%) between years 2 and 3 having an increase in JSW.  
 
To date, no studies have been identified that apply the RC index methodology within 
musculoskeletal research, not only to monitor joint space measurements but also assess disease 
deterioration. The RC index has, however, been successfully applied within psychological and 
neurological research. For example Ferguson et al used the RC index to determine clinically 
significant change between pre- and post-intervention SF-36 scores that provide a continuous 




technique, as assessing crude differences alone does not provide reliable information about 
whether an intervention has had clinically meaningful effects (26, 27).  However an assumption 
of the RC index is stability measurements between time points and so this method has not been 
previously applied to assess deterioration. The natural disease progression of OA is a slow 
process, often taking many years. Therefore the assumption would be that on an annual basis 
little or no change in JSW in a study participant would have occurred, and so in this new and 
novel application of the RC index the assumption of stability was upheld.  
 
There are other statistical techniques and metrics currently used within musculoskeletal 
research to identify whether change has been significant, such as the standard error of the 
measurement (SEM) or standardized response mean (SRM). However neither of these 
techniques are appropriate for assessment at the individual level rather the population level. 
Therefore an advantage of using the RC index is that reliability of an individual study 
participant’s change can be determined, and additionally the estimate of the standard error used 
within the RC index calculation can be used to quantify the JSW change above which change 
could be considered statistically reliable. Although the RC index has its merits, there has also 
been much debate and criticism of the technique (24, 28). One of the major criticisms is that, 
although all variations of the calculation can be simplified to the same fundamental expression, 
each approach differs slightly in how the elements of the RC index are calculated. For example, 
the original definition of the RC index developed by Jacobson and Traux(14) requires an 
externally-derived test-retest reliability coefficient to be able to calculate the standard error and 
assumes equal variance in the measurements at both time points. Hinton-Bayre has made a 
comparison of the different RC variations but there is currently no consensus as to which RC 





A further criticism of the RC index is that the index is specific but not very sensitive, but this 
is partly due to the magnitude of measurement error within longitudinal studies. Within this 
study the conventional 5% level of significance was followed, meaning that the cut-point for 
RC index scores was ±1.96, but this is an arbitrary cut-point and to increase the sensitivity of 
the RC index a less strict cut-off could be used.   
 
The RC index aims to distinguish true progression of JSN in those with knee OA from 
measurement error. Although use of JSW longitudinally is the current gold standard for 
monitoring disease progression, previous studies have shown that inconsistent knee positioning 
during radiographs can cause a systematic shift in JSW (10) and so change in JSW may be due 
to change in positioning of the knee during radiograph rather than disease progression. 
However, previous studies have shown that the use of the inter-margin distance is optimal in 
reducing variation in JSW due to knee positioning (29). The minimal JSW (mm) at the medial 
tibiofemoral compartment, the inter-margin distance, was measured in SEKOIA annually from 
radiographs obtained under strict study protocol (20, 23). Therefore the data in this study were 
collected with all the associated safeguards around methodology and training, and all 
radiographs were assessed by one reader, thus reducing measurement error. It is thus likely that 
the joint space measurements collected during the SEKOIA study contain less measurement 
error than routine clinical measurements. As there are different radiographic techniques that 
can be used to obtain knee radiographs it would be important to assess the use of the RC index 
in data where other methods have been used, particularly in routine clinical practice. However,  
it is important to remember that the RC index only indicates statistically reliable change and 




distinguish changes in JSW due to variability in the radiographic positioning from disease 
progression.  
 
As there is no ‘gold standard’ method for assessing statistically significant change in JSW when 
assessing OA disease progression, there is no comparator for the RC index. However, the use 
of this novel approach does take account of measurement error, unlike calculation of crude 
differences. The formula is also simple enough that summary statistics derived from the study 
population enable assessment of individual study participants’ reliable change  
 
Despite its simplicity, a conceptual problem with the RC index is that no account is taken within 
the calculation of the duration between the study visits. However application of the RC index 
informs of thresholds which can be used to further explore change, particularly in a clinical 
trial setting. It can help with determining study duration and assist in sample size determination. 
It is also possible that once calculated, the RC index groupings and individual scores could also 
be used in further statistical analysis to investigate characteristics and phenotypes which may 
be associated with disease progression, after accounting for the presence of measurement error.  
 
There are some limitations to this study. The study participants already had established OA 
when recruited into SEKOIA and it would be of value to assess the performance of the RC 
index in a population with wider variability in JSW. It is notable that the RC index did not 
remove all apparent increases in JSW. No measure is entirely reliable and there is always a 
balance between the sensitivity and specificity of the cut points chosen. To eliminate all 




calculation, though this would reduce the number of decreases identified. Alternatively, if the 
concern was about missing true deterioration, a lower level could be used. 
 
Few studies have assessed long-term reduction of joint space in a population of patients with 
OA of the knee. Applying the RC index within knee OA disease progression studies should 
enable a greater understanding of the progression of JSN. If the value of RC indices is 
confirmed in other populations it may aid research, lead to better management of patients with 
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Table 1 Participants characteristics 
 Men 
(n = 167 ) 
 Women 
(n = 392) 
 All 
 (n=559)    
 Mean SD  Mean SD  Mean SD 
Age (years)  63.8 7.8  62.3 7.3  62.8 7.5 
BMI (Kg/m2)  29.8 4.1  29.8 5.5  29.8 5.1 





















Joint space narrowing 







         
 Minimum Maximum  Minimum Maximum  Minimum Maximum 














Joint space narrowing 







         
 Median Range  Median Range  Median Range 
Disease duration (months) 58 0 - 502  49 0 - 457  51 0 - 502 
         
 n %  n %  n % 







2 103 61.7  247 63.0  350 62.6 







Table 2 Crude changes and Reliable Change Index results 
  Baseline to year 1 Year 1 to year 2  Year 2 to year 3 
 
N N  N 
Total in study 465 400  329 
 
N % N %  N % 
Crude increase 146 31.4 171 42.8  138 41.9 
Crude decrease 319 68.6 229 57.3  191 58.1 
RCI increase  5 1.1 5 1.3  3 0.9 
RCI decrease 28 6.0 18 4.5  13 4.0 
















Table 3 Crude changes, radiological progressors and Reliable Change Index results 
  
Baseline to year 3 
(total study duration) 
 
N 
Total in study 336 
 
N % 
Crude increase 74 22.0 
Crude decrease 262 78.0 
Radiological progressor (JSN of 0.5mm) 120 35.7 
Radiological progressor (JSN of 0.8mm) 62 18.5 
RCI increase  1 0.3 
RCI decrease  36 10.7 
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